The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo

[1]  C. Berteotti,et al.  CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling , 2019, Brain pathology.

[2]  E. Pestana-Knight,et al.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. , 2019, Pediatric neurology.

[3]  F. Jensen,et al.  AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder , 2019, The Journal of Neuroscience.

[4]  K. Ye,et al.  Functional and Structural Impairments in the Perirhinal Cortex of a Mouse Model of CDKL5 Deficiency Disorder Are Rescued by a TrkB Agonist , 2019, Front. Cell. Neurosci..

[5]  M. Hagiwara,et al.  DYRK1A and cognition: A lifelong relationship , 2019, Pharmacology & therapeutics.

[6]  Z. Xiong,et al.  Molecular and Synaptic Bases of CDKL5 Disorder , 2018, Developmental neurobiology.

[7]  Tim Guilliams,et al.  The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5 , 2018, Human molecular genetics.

[8]  S. Bastianini,et al.  CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder , 2018, Human molecular genetics.

[9]  E. Ciani,et al.  Treatment with the GSK3‐beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice , 2018, The European journal of neuroscience.

[10]  S. Cobb,et al.  CDKL5 variants , 2017, Neurology: Genetics.

[11]  Wenlin Liao,et al.  Mice lacking cyclin‐dependent kinase‐like 5 manifest autistic and ADHD‐like behaviors , 2017, Human molecular genetics.

[12]  T. Manabe,et al.  CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility , 2017, Neurobiology of Disease.

[13]  Y. Hérault,et al.  Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature , 2017, Expert opinion on therapeutic patents.

[14]  A. Neves,et al.  Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems , 2017, BioMed research international.

[15]  B. Wu,et al.  Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development , 2017, Molecular Psychiatry.

[16]  J. Thornton,et al.  Structural analysis of pathogenic mutations in the DYRK1A gene in patients with developmental disorders , 2017, Human molecular genetics.

[17]  M. Giustetto,et al.  Lack of Cdkl5 Disrupts the Organization of Excitatory and Inhibitory Synapses and Parvalbumin Interneurons in the Primary Visual Cortex , 2016, Front. Cell. Neurosci..

[18]  M. Giustetto,et al.  Dendritic Spine Instability in a Mouse Model of CDKL5 Disorder Is Rescued by Insulin-like Growth Factor 1 , 2016, Biological Psychiatry.

[19]  R. Bartesaghi,et al.  HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. , 2016, Human molecular genetics.

[20]  J. Pujol,et al.  Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[21]  Y. Hérault,et al.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome , 2016, Front. Behav. Neurosci..

[22]  T. Rajkumar,et al.  Repeated dose studies with pure Epigallocatechin-3-gallate demonstrated dose and route dependant hepatotoxicity with associated dyslipidemia , 2016, Toxicology reports.

[23]  Tiziana Alberio,et al.  CDKL5 and Shootin1 Interact and Concur in Regulating Neuronal Polarization , 2016, PloS one.

[24]  Neha Singh,et al.  Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG) , 2015, Nutrition Journal.

[25]  R. Bartesaghi,et al.  Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder , 2015, Neurobiology of Disease.

[26]  T. Copf.  Importance of gene dosage in controlling dendritic arbor formation during development , 2015, The European journal of neuroscience.

[27]  P. Stankiewicz,et al.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications , 2014, European Journal of Human Genetics.

[28]  C. Gross,et al.  Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling , 2014, Neurobiology of Disease.

[29]  M. Giustetto,et al.  Mapping Pathological Phenotypes in a Mouse Model of CDKL5 Disorder , 2014, PloS one.

[30]  S. Siegel,et al.  Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice , 2012, Proceedings of the National Academy of Sciences.

[31]  R. Kiss,et al.  DYRK1A kinase inhibitors with emphasis on cancer. , 2012, Mini reviews in medicinal chemistry.

[32]  V. Kalscheuer,et al.  CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons , 2012, Nature Cell Biology.

[33]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.

[34]  Mohammed A. Islam,et al.  Cardiovascular effects of green tea catechins: progress and promise. , 2012, Recent patents on cardiovascular drug discovery.

[35]  K. Chung,et al.  Dyrk1A negatively regulates the actin cytoskeleton through threonine phosphorylation of N-WASP , 2012, Journal of Cell Science.

[36]  N. Landsberger,et al.  Extrasynaptic N-Methyl-d-aspartate (NMDA) Receptor Stimulation Induces Cytoplasmic Translocation of the CDKL5 Kinase and Its Proteasomal Degradation* , 2011, The Journal of Biological Chemistry.

[37]  H. Gainer,et al.  PSD-95 Is Required to Sustain the Molecular Organization of the Postsynaptic Density , 2011, The Journal of Neuroscience.

[38]  Z. Xiong,et al.  CDKL5, a Protein Associated with Rett Syndrome, Regulates Neuronal Morphogenesis via Rac1 Signaling , 2010, The Journal of Neuroscience.

[39]  W. Becker,et al.  Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation , 2009, The FEBS journal.

[40]  N. Landsberger,et al.  CDKL5 Expression Is Modulated during Neuronal Development and Its Subcellular Distribution Is Tightly Regulated by the C-terminal Tail* , 2008, Journal of Biological Chemistry.

[41]  S. Shankar,et al.  Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[42]  G. Forlani,et al.  Functional Consequences of Mutations in CDKL5, an X-linked Gene Involved in Infantile Spasms and Mental Retardation* , 2006, Journal of Biological Chemistry.

[43]  L. Wales.  Functional and structural , 1999 .

[44]  X. Estivill,et al.  Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. , 1999, Genomics.

[45]  M. Laguerre,et al.  Epigallocatechin 3-Gallate as an Inhibitor of Tau Phosphorylation and Aggregation: A Molecular and Structural Insight. , 2017, The journal of prevention of Alzheimer's disease.

[46]  Inhibition of GSK 3 β rescues hippocampal development and learning in a mouse model of CDKL 5 disorder , 2015 .

[47]  N. Pundir,et al.  International Standard Serial Number (issn): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences Therapeutic Potential of Nicorandil International Standard Serial Number (issn): 2319-8141 , 2022 .